Biontech and fosun pharma to supply china with mrna-based covid-19 vaccine

Mainz, germany, and shanghai, china, december 16, 2020 (globe newswire) — biontech se (nasdaq: bntx, “biontech” or “the company”) and shanghai fosun pharmaceutical (group) co., ltd. (“fosun pharma” or “group”; stock code: 600196.sh, 02196.hk) today announced an agreement to supply mainland china with an initial 100 million doses of their bnt162 mrna-based vaccine candidate against covid-19 in 2021, subject to regulatory approval. initial supply will be delivered from biontech's production facilities in germany. 
BNTX Ratings Summary
BNTX Quant Ranking